Abstract. Malignant melanoma predominantly occurs in the skin and mucous membranes, thus, malignant melanoma of the breast is particularly rare. In the current study, a case of a 26-year-old female with a malignant melanoma of the breast is presented. On diagnosis of the patient, extensive metastasis had occurred. The patient refused any treatment and succumbed two months after the initial diagnosis. The prognosis for patients with this rare tumour of the breast is somewhat poor. Early diagnosis, correct surgical resection and comprehensive adjuvant therapy are the key procedures that may improve the patient survival rate. The current case report aims to increase the awareness of uncommon tumours of the breast.

Introduction

Malignant melanoma predominantly occurs in the skin, mucous membranes and the choroid. Malignant melanoma of the breast is particularly rare. The incidence of primary melanoma of the breast is <5% of all melanomas (1). Observation of the clinical pathological features, immunohistochemical staining methods and tissue tissue origin are required to identify primary malignant melanoma of the breast, as well as other types of breast tumour. Surgical resection is the commonly adopted treatment method for malignant melanoma, supplemented by chemo-, radio- and immunotherapy treatments resulting in a comprehensive treatment strategy.

In the current study, a 26-year-old female patient exhibiting a primary malignant melanoma of the breast is presented, and the clinical and pathological features, diagnosis and treatments are discussed in correlation with the literature. Patient provided written informed consent.

Case report

A 26-year-old female was admitted to the Department of General Surgery of Daping Hospital and Research Institute of Surgery (Chongqing, China), due to the presence of a painless mass in the left breast for three months. The patient indicated that the mass had recently grown rapidly. Early diagnosis, correct surgical resection and comprehensive adjuvant therapy are the key procedures that may improve the patient survival rate. The current case report aims to increase the awareness of uncommon tumours of the breast.
Discussion

Malignant melanoma is a highly malignant tumour that is derived from melanocytes. The incidence of malignant melanoma has risen markedly over the last decade. It occurs anywhere on the body, however, is commonly found in the skin, mucous membranes and the choroid. Primary melanoma of the breast is particularly rare, with an incidence of <5% of all malignant melanomas (1,2). The aetiology of malignant melanoma remains unknown. It is generally hypothesised to be associated with excessive exposure to ultraviolet radiation from the sun. In addition, it is associated with ethnicity, the endocrine and immune systems, chronic stimulation and improper surgery may cause the progression of nevus into malignant melanoma.

Malignant melanoma of the breast has four predominant manifestations: i) Primary malignant melanoma of the breast skin; ii) malignant melanoma metastasis to the breast; iii) in-transit metastases to breast tissue and skin; and iv) primary malignant melanoma of the breast gland (1). The diagnosis of primary malignant melanoma of the breast is highly dependent on pathological morphology, immunohistochemistry and electron microscopy, amongst other diagnostic techniques, and the following should be noted during diagnosis: i) Pleomorphism of tumour cells and nuclear atypia; ii) scattered intracellular pigment granules (although there are 6-10% of malignant melanomas exhibiting little or no pigment, which are termed amelanotic melanoma) (3); iii) immunohistochemistry results demonstrating positive expression of the proteins S-100, HMB-45 and melan-A (4); iv) electron microscopy identifying melanosome and former melanosome (5); v) the edge of the tumour tissue and normal breast tissue does not exhibit a transition; and vi) exclusion of tumour metastases and tumor invasion from neighboring sites. The diagnosis of malignant melanoma is occasionally particularly complex and, therefore, requires the use of immunohistochemical staining for its identification. Positive expression of S-100 is an exceptionally sensitive indicator for malignant melanoma, however, it is also expressed in 50% of breast cancer cases. Therefore it must be observed in combination with a positive expression of HMB-45 and melan-A for the diagnosis of primary melanoma of the breast. Whereas other indicators, such as CK, vimentin and SMA, demonstrate a negative expression and signal the presentation of other types of tumours. Furthermore, Ki-67 staining may be used to distinguish between benign and malignant tumours (6,7).

In the present study, the first symptom that was noted by the patient was the tumour in the left breast. Based on the clinical examination, histopathological features and results from immunohistochemical staining, the patient was diagnosed with a primary malignant melanoma of the breast.

The treatment of primary malignant melanoma of the breast is the same as that for other malignant melanoma
located elsewhere on the body. The primary treatment method is surgical resection, with an appropriate combination of chemo-, radio-, immuno- and targeted therapy (1,8). Wide local excision is the predominant surgical approach. It is generally hypothesised that a cutting edge of 2 cm ensures the reliability of the surgery. A mastectomy does not improve the patient's prognosis, and a comprehensive axillary lymph node dissection is required when preoperative axillary lymph node metastasis is identified and confirmed. A sentinel lymph node biopsy reduces the requirement for an unnecessary lymph node dissection (9,10).

The role of adjuvant chemo- or radiotherapy, either singularly or in combination, remains unknown with regard to their efficacy in malignant melanoma. Chemotherapy is commonly used for pre- and postoperative adjuvant therapy and for those who are not suitable for, or refuse, surgery or for those patients who exhibit widespread metastases. The chemotherapy programme is usually with a dacarbazine-based treatment plan, however, the effective rate is only 7-13% (11). Other commonly used agents include temozolomide, cisplatin and taxol; multi-agent chemotherapy may improve the treatment outcome. Adjuvant radiotherapy may be performed when removal of the lesion is not possible, there are positive margins, the lymph node size is >3 cm, the number of lymph nodes involved exceeds four or when there is local recurrence or distant metastases. Although adjuvant radiotherapy decreases the local regional failure from 30 to 10%, the survival rate of patients remains unchanged (12,13).

Malignant melanoma is an immunogenic tumour and adjuvant immunotherapy is associated with high-risk tumours. Interferon, interleukin-2 and other biological response modifiers for malignant melanoma have a moderate effect. It is reported that immunotherapy in combination with chemotherapy may improve the efficiency of patient treatment, however, the long-term effects require further investigation (14-16).

In recent years, numerous novel biological and molecular targeted therapies have been adopted for the treatment of malignant melanoma. Clinical studies have identified that ipilimumab (a monoclonal antibody that blocks cytotoxic T lymphocyte-associated antigen 4) and vemurafenib (oncopgenic BRAF-inhibitor agent) improve the overall response rate, and prolong the progression-free survival and overall survival for advanced malignant melanoma patients. However, the specific efficacy is currently being investigated and evaluated (17-19).

In conclusion, primary malignant melanoma of the breast is a particularly rare type of tumour and the prognosis is somewhat poor. The diagnosis depends on histopathological assessment and immunohistochemical staining combined with a detailed clinical history and careful physical examination. Early diagnosis, correct surgical resection and comprehensive adjuvant therapy are significant factors for improving the patient survival rate.

Acknowledgements

The present study was supported by the Natural Science Foundation of Chongqing (project no. CSTC, 2011BB5032).

References

1. Kurul S, Taş F, Büyükkabani N, et al: Different manifestations of malignant melanoma in the breast: a report of 12 cases and a review of the literature. Jpn J Clin Oncol 35: 202-206, 2005.
2. Alžaraa A and Sharma N: Primary cutaneous melanoma of the breast: A case report. Cases J 1: 212, 2008.
3. Duggal R and Srinivasan R: Primary amelanotic melanoma of the cervix: case report with review of literature. J Gynecol Oncol 21: 199-202, 2010.
4. Bonetti F, Pea M, Martignoni G, et al: False-positive immunostaining of normal epithelia and carcinomas with ascites fluid preparations of antimeelanoma monoclonal antibody HMB45. Am J Clin Pathol 95: 454-459, 1991.
5. Taatjes DJ, Arendash-Durand B, von Turkovich M and Trainer TD: HMB-45 antibody demonstrates melanosome specificity by immunoelectron microscopy. Arch Pathol Lab Med 117: 264-268, 1993.
6. Ohsie SJ, Sarantopoulos GP, Cochran AJ and Binder SW: Immunohistochemical characteristics of melanoma. J Cutan Pathol 35: 433-444, 2008.
7. Lee AH: Use of immunohistochemistry in the diagnosis of problematic breast lesions. J Clin Pathol 66: 471-477, 2013.
8. Davar D, Tarhini AA and Kirkwood JM: Adjuvant therapy for melanoma. Cancer 18: 192-202, 2012.
9. Biswas A, Goyal S, Jain A, et al: Primary amelanotic melanoma of the breast: combating a rare cancer. Breast Cancer 21: 236-240, 2014.
10. Thompson JF, McCarthy WH, Bosch CM, et al: Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 5: 255-260, 1995.
11. Avril MF, Aamdal S, Grob JJ, et al: Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22: 1118-1125, 2004.
12. Lee RJ, Gibbs JF, Proulx GM, et al: Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 46: 467-474, 2000.
13. Calabro A, Singletary SE and Balch CM: Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 124: 1051-1055, 1989.
14. Thompson JF, Scolyer RA and Kefferd RF: Cutaneous melanoma. Lancet 365: 687-701, 2005.
15. Verma S, Quiet I, McCready D, et al: Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 106: 1431-1442, 2006.
16. Hauschild A, Weichenthal M, Rass K, et al: Efficacy of low-dose interferon α2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. J Clin Oncol 28: 841-846, 2010.
17. Chapman PB, Hauschild A, Robert C, et al: BRIM-3 Study Group: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011.
18. Ribas A, Hersey P, Middleton MR, et al: New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res 18: 336-41, 2012.
19. Spagnolo F and Queirolo P: Upcoming strategies for the treatment of metastatic melanoma. Arch Dermatol Res 304: 177-184, 2012.